Key result
Degarelix treatment rapidly resolved bleeding symptoms and normalized hematological and biochemical indices in a patient with disseminated intravascular coagulation caused by advanced prostate cancer.
Case Report (n=1)
No
Degarelix rapidly controlled DIC secondary to advanced metastatic prostate cancer.
Degarelix may rapidly control prostate cancer-associated DIC; single case leaves open need for prospective trials before clinical adoption.
Disseminated intravascular coagulation (DIC) is an acquired syndrome that develops as a result of an underlying disorder, and is characterized by a consumptive coagulopathy that induces hemorrhage and microclot formation. Most frequently, it develops as a result of sepsis and trauma, but can infrequently be induced secondary to malignancy. Herein, we outline the management of a patient with an occult diagnosis of metastatic prostate cancer who presented with DIC. World J Nephrol Urol. 2015;4(3):240-241 doi: http://dx.doi.org/10.14740/wjnu223w
No takes yet. Share an insight, caveat, or question.
Looney et al. (2015) conducted a case report in Metastatic prostate cancer with disseminated intravascular coagulation (n=1). Degarelix was evaluated on Resolution of bleeding symptoms and normalization of hematological indices. Degarelix treatment rapidly resolved bleeding symptoms and normalized hematological and biochemical indices in a patient with disseminated intravascular coagulation caused by advanced prostate cancer.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: